DC-CIK细胞联合常规治疗对肾透明细胞癌患者的临床疗效  

Clinical evaluation of dendritic cell-cytokine induced killer cells immunotherapy combined with conventional treatment in patients with renal carcinoma

作　　者：谢云青[1] 陈莉[1] 杨建伟[2] 陈路川[3] 刘施佳[1] 应敏刚[3] 郑秋红[1] 

机构地区：[1]福建医科大学附属福建省肿瘤医院福建省肿瘤生物治疗重点实验室,福建福州350014 [2]福建医科大学附属福建省肿瘤医院腹部肿瘤内科,福建福州350014 [3]福建医科大学附属福建省肿瘤医院腹部肿瘤外科,福建福州350014

出　　处：《中国肿瘤生物治疗杂志》2017年第6期665-669,共5页Chinese Journal of Cancer Biotherapy

基　　金：福建省自然基金资助项目(No.2016J01514);福建省科技计划项目(No.2017Y0022)~~

摘　　要：目的:探讨DC-CIK细胞治疗肾透明细胞癌临床疗效及治疗次数对患者预后的影响。方法:回顾性分析2004年1月至2011年6月在福建省肿瘤医院诊疗的100例肾透明细胞癌患者,其中63例在福建省肿瘤生物治疗重点实验室进行自体DC-CIK细胞免疫治疗联合常规治疗为DC-CIK细胞治疗组,其余37例未经DC-CIK细胞治疗为对照组,比较两组患者的5年DFS和OS。治疗组按照DC-CIK细胞治疗疗程数分成≤3个疗程组及>3个疗程组,分析DC-CIK细胞治疗疗程数对肾透明细胞癌患者5年DFS和OS的相关性。结果:DC-CIK细胞治疗组患者5年OS较对照组明显提高(81.05%vs 60.29%,P<0.05),但5年DFS无显著性差异(P>0.05);DC-CIK细胞治疗疗程数>3个的患者5年OS较对照组明显提高(P<0.05),但5年DFS无显著性差异(P>0.05)。结论:自体DC-CIK细胞回输联合常规治疗手段治疗肾透明细胞癌更有生存优势,且DC-CIK细胞治疗疗程数与肾透明细胞癌患者的预后密切相关。Objective：To evaluate the clinical efficacy of adjuvant dendrtic cell （DC）-cytokine-induced killer （CIK） cells immunotherapy and the effect of DC-CIK cells treatment courses on the prognosis of patients with renal clear cell car- cinoma. Methods： One hundred patients with renal clear cell carcinoma treated in Fujian Provincial Tumor Hospital from Jan, 2004 to Jun, 2011 were included in this retrospective study; 63 patients received DC-CIK cells immunotherapy com- bined with conventional therapy were regarded as DC-CIK cells treatment group, while the other 37 patients didnt receive DC-CIK cells therapy were regarded as control group. The 5-year DFS and OS of the two groups were compared. The treat- ment group was further sub-grouped according to the course 〉 3 and course ≤ 3, and the 5-year DFS and OS were further compared between the two sub-groups. Results： Survival analysis showed the 5-years overall survival （OS） rate was sig- nificantly higher in the DC-CIK group compared with the control group （ 81.05% vs 60.29% , P 〈 0.05 ）, however, there was no significant difference in 5-year DFS rate between two groups. Further subgroup analysis stratified according to the course of DC-CIK cells treatment showed that the 5-years OS was significantly improved in the group with course greater than 3 （ P 〈 0.05 ）, although there was no significant difference in 5-years DFS rate between two subgroups （ P 〉 0.05 ）. Conclusion： Our results demonstrated that renal carcinoma patients could benefit from autologous DC-CIK cells immuno- therapy in combination with conventional therapies in terms of increasing overall survival. And the course of DC-CIK cells treatment is closely related with the prognosis of patients with renal cell carcinoma.

关 键 词：肾透明细胞癌 DC-CIK细胞 免疫治疗 临床疗效 

分 类 号：R737.11[医药卫生—肿瘤] R730.51[医药卫生—临床医学]